CARGO Therapeutics to Discontinue FIRCE-1 Phase 2 Study of Firi-cel; Advances Remaining Programs While Evaluating Strategic Options | CARGO Therapeutics, Inc.
CARGO elects to discontinue FIRCE-1, a Phase 2 clinical study of firicabtagene autoleucel (firi-cel) 1 ; Company believes results do not support a competitive benefit-risk profile for patients. CARGO ...
